

NOT FOR PUBLICATION

COMMISSION ON HUMAN MEDICINES (CHM)

COVID-19 VACCINES BENEFIT RISK EXPERT WORKING GROUP

Minutes of the meeting held on **Friday 20th November 2020** at **14:30** via videoconference

Participants Present

Members

Professor Sir M Pirmohamed (Chair)
Professor J Breuer
Professor G Dougan
Professor N French
Professor D Goldblatt
Ms S Hunneyball
Professor K Hyrich
Sir M Jacobs
Professor H J Lachmann
Professor P J Lehner
Dr S Misbah
Professor S Price
Dr A Riordan
Professor C Robertson
Professor P Shah
Professor T Solomon
Dr R Thorpe
Mrs M Wang
Professor C Weir

Members of the CTBV Expert Advisory Group

Professor B K Park
Professor M Turner

Members of the CPS Expert Advisory Group

Mr VI G Fenton-May
Mr R Lowe
Professor Y Perrie
Professor K M G Taylor (Chair of CPS)
Dr S Walsh

Observer

Professor S Ralston (Chair of CHM)

Professional Staff of MHRA Present

Principal Assessors

Dr J Bonnerjea - LD
[REDACTED] - LD

MHRA Observers

[REDACTED] - VRMM
[REDACTED] - LD
[REDACTED] - MHRA-NIBSC
[REDACTED] - LD
[REDACTED] - LD
Dr S Branch - VRMM
[REDACTED] - LD
[REDACTED] - LD
[REDACTED] - LD
[REDACTED] - LD
[REDACTED] - MHRA-NIBSC
[REDACTED] - VRMM
Mr K McDonald - LD
[REDACTED] - LD
[REDACTED] - LD
Dr N Rose - MHRA-NIBSC
Dr C Schneider - MHRA-NIBSC
[REDACTED] - LD
[REDACTED] - LD
[REDACTED] - LD
[REDACTED] - LD

NOT FOR PUBLICATION

Presentations

COG-UK

[REDACTED]
[REDACTED]

Pfizer/BioNTech

[REDACTED]
[REDACTED]

Moderna

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Secretariat

[REDACTED]
[REDACTED]
[REDACTED]

Key

LD = Licensing Division

NIBSC = National Institute for Biological Standards & Control

VRMM = Vigilance & Risk Management of Medicines

CTBV = Clinical Trials, Biologicals & Vaccines EAG

CPS = Chemistry, Pharmacy & Standards EAG

PHE = Public Health England

CHM = Commission on Human Medicines

[REDACTED]

7th December 2020

1. Introduction and Announcement

1.1 The Chair reminded Members that the content of papers and proceeding of the meeting are strictly confidential and should be treated as 'Official – sensitive commercial' and should not be disclosed. There is no consent for members / participants to record the meeting, take screenshots or photographs of presentations.

1.2 The Chair informed members and participants that this is a call for evidence meeting.

The Chair welcomed the presenters at today's meeting.

2. The EWG heard presentations from COG-UK, [REDACTED], Research Associate at the University of Cambridge now coordinating all the activities of the mutational analysis and tracking working group for the COG-UK consortium.

3. The EWG also heard presentations from Pfizer/BioNTech, [REDACTED] [REDACTED] [REDACTED] and [REDACTED] and from Moderna, [REDACTED].

4. Any Other Business

4.1 Members have been asked to review Information Security Briefing on Covid-19 Vaccine Data and confirm that they understand and agree to adhere to the protocols.

The Meeting started at 14:32 and ended at 16:10.

Members are reminded that the content of papers and proceeding of the meetings are to be treated as 'Official – sensitive commercial'. Members are also reminded that, in accordance with the Code of Practice, they should declare any financial interests (personal or non-personal, specific or non-specific) which they have, or which an immediate family member has, in any of the agenda items. Members must also declare any other matter which could reasonably be perceived as affecting their impartiality. Detailed guidance is set out in the Code of Practice